Alberto Picca

📢 [Nouvelle publication] : résultats d'un essai thérapeutique explorant l’efficacité du traitement par fexagratinib dans un sous-type de gliome diffus 👉Pour en savoir plus : curamus-cancer.fr/%f0%9f%93%a2pu… @alberto_picca

📢 [OPEN REGISTRATIONS & CALL FOR ABSTRATCS] - Brain Tumor Microenvironment Symposium - 30th & 31st January 2025 - Paris The SiRIC CURAMUS is delighted to organize its very first Brain Tumor Microenvironment Symposium ! 👉 Program and registrations: my.weezevent.com/brain-tumor-mi…

📢 Only a few days left to register for the Oligodendroglioma Workshop that will take place the 20 & 21 september 2024 at the @InstitutCerveau in Paris, to mark the 15th anniversary of the POLA rare cancer network ! 👇 my.weezevent.com/oligodendrogli…

Happy to share our preprint! A big thank you to all the collaborators, co-authors, and everyone involved in this study. Feel free to contact us to discuss our findings; your scientific feedback is more than welcome. biorxiv.org/content/10.110…

📢New preprint alert: #Benchmarking second-generation methods for cell-type #deconvolution of #transcriptomic data doi.org/10.1101/2024.0… A thread 🧵👇 1/

For those who check model assumptions (you ALL should), the {easystats} package makes it very easy to do this with various models but particularly regression models

Our congress always aims to reflect the interests and concerns of the neurology community, and your contributions play a huge part in helping to achieve that. 📆 Abstract submission deadline: Friday, 2 February 🔗 Learn more: ow.ly/KH2y50QviTS #EAN2024 #EANeurology

#RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade #Gliomas in Adults ascopubs.org/doi/10.1200/JC… #btsm #neuroradiology @JCO_ASCO

Marie Curie died of aplastic anaemia on 4 July 1934, a result of years of exposure to radiation through her work. Even today her laboratory notebook from 1899-1902, is radioactive and will be for 1,500 years.

Each year on June 8, #WorldBrainTumorDay is observed to raise awareness & educate people about brain tumors. EANO is dedicated to promote advances in #NeuroOncology through innovative research & concerted education & training. Together, we can make a difference! #btsm @OncoAlert

#Vorasidenib in IDH1- or IDH2-Mutant Low-Grade #Glioma | NEJM. nejm.org/doi/full/10.10… #btsm #idh @NEJM

If you're looking for the next opportunity to advance your #NeuroOncology education, plan to attend #EANO2023 in Rotterdam, NL. Get the latest information on #NeuroSurgery #Neuropathology #braintumor #Neuroimaging #Immunotherapy et al. Learn more eano.eu/eano2023/ #btsm

NEW content online! Dynamics and specificities of T cells in cancer immunotherapy dlvr.it/SmNW6K

🚨Today, April 12 at 23:59 hrs CEST is the very last day to submit your abstract for #EANO2023. We’re very excited to see so many submissions & are looking forward to your presentations! eano.eu/eano2023/abstr… #NeuroOncology #btsm @OncoAlert @theIBTA @EuropeanCancer @NeuroOnc

@michelle_monje Crystal Mackall & colleagues describe a localized toxicity syndrome associated with #immunotherapy treatment for CNS tumors, and propose a new grading scale to help standardize reporting and promote research. @StanfordMed #CARTtherapy nature.com/articles/s4159…

✨DON’T MISS THIS @NatureCancer PERSPECTIVE – “Targeting public neoantigens for cancer immunotherapy” #ShibinZhou & Co. Find it here👇 nature.com/articles/s4301… rdcu.be/c772D

🚨 Still working on your abstract submission for #EANO2023? Don’t panic: The submission deadline has been extended until April 12, 23:59 CEST. 👉eano.eu/eano2023/abstr…… #neurosurgery #NeuroOncology #btsm @OncoAlert @theIBTA @EuropeanCancer @EditorNeuro @BNOSofficial @GrupoGeino

#NeuroOncology Youngsters! Take an active part to share knowledge & make progress for patients with brain tumors. Submit your abstract to #EANO2023 by April 6, 2023 at 23:59 hrs CEST 👉eano.eu/eano2023/abstr… #btsm #neurosurgery #glioma #Immunotherapy #pathophysiology @OncoAlert

Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4– and PD-1–targeted immunotherapy science.org/doi/10.1126/sc…